A Phase 2 interventional study of brentuximab vedotin in Hodgkin Lymphoma, Peripheral T Cell Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Seagen Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-13.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 72nd largest by enrollment, is one of 5 that started in 2019, is one of 41 in phase 2, and was the 64th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 20th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 2, and was the 19th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.
This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T cell lymphoma (PTCL) who experienced complete response (CR) or partial response (PR) with a brentuximab vedotin-containing regimen and subsequently experienced disease progression or relapse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: brentuximab vedotin
1.8 mg/kg given intravenously (IV)
Also known as: ADCETRIS, SGN-35
Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on BICR
Time frame: Up to 18.3 months
Number of Participants With Adverse Events
An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
Time frame: Up to 36 months
Number of Participants With Laboratory Abnormalities
Laboratory data was summarized by the worst post-baseline grade, by NCI CTCAE v5.0 or higher for each parameter.
Time frame: Up to 36 months
Duration of Response (DOR) Per BICR According to Modified Lugano Response Criteria
Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.
Time frame: Up to 17.1 months
Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.
Time frame: up to 18.3 months
Overall Survival (OS)
OS is defined as the time from date of enrollment to date of death due to any cause.
Time frame: Up to 35.8 months
Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria
CR rate is defined as the percentage of participants with CR according to the modified Lugano Criteria for Response Assessment (Cheson 2014)
Time frame: Up to 18.3 months
ORR Per Investigator Assessment According to Modified Lugano Response Criteria
Objective Response Rate (ORR) is defined as the percentage of participants with CR or PR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on investigator assessment
Time frame: Up to 18.3 months
DOR Per Investigator Assessment According to Modified Lugano Response Criteria
Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.
Time frame: Up to 17.1 months
Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.
Time frame: Up to 18.3 months
Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria
CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014).
Time frame: Up to 18.3 months
ORR Per BICR According to Lugano Response Criteria
ORR is defined as the percentage of participants with CR or PR, assessed according to Lugano Criteria for Response Assessment (Cheson 2014)
Time frame: Up to 18.3 months
| Milestone | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Started | 6 | 6 |
| Completed | 0 | 0 |
| Not completed | 6 | 6 |
| Withdrew: Study closure by sponsor | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 0 | 2 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on BICR
| percentage of participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Objective Response Rate (ORR) Per BICR According to Modified Lugano Response Criteria | 40.0 (5.3 to 85.3) | 83.3 (35.9 to 99.6) |
An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
| Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Any TEAE | 5 | 6 |
| Treatment-related TEAE | 4 | 5 |
| Any Treatment-Emergent SAE | 0 | 2 |
| Discontinuation of treatment due to TEAE | 1 | 3 |
| Discontinuation of treatment due to treatment-related TEAE | 1 | 3 |
| TEAE leading to death | 0 | 0 |
Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.
| months | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Duration of Response (DOR) Per BICR According to Modified Lugano Response Criteria | NA (NA to NA) | NA (2.9 to NA) |
Laboratory data was summarized by the worst post-baseline grade, by NCI CTCAE v5.0 or higher for each parameter.
| Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Hemoglobin Low, Grade 1-2 | 3 | 2 |
| Hemoglobin Low, Grade 3 | 0 | 0 |
| Hemoglobin Low, Grade 4 | 0 | 0 |
| Leukocytes Low, Grade 1-2 | 1 | 2 |
| Leukocytes Low, Grade 3 | 0 | 0 |
| Leukocytes Low, Grade 4 | 0 | 0 |
| Lymphocytes Low, Grade 1-2 | 1 | 1 |
| Lymphocytes Low, Grade 3 | 0 | 1 |
| Lymphocytes Low, Grade 4 | 0 | 0 |
| Neutrophils Low, Grade 1-2 | 0 | 2 |
| Neutrophils Low, Grade 3 | 0 | 1 |
| Neutrophils Low, Grade 4 | 0 | 0 |
| Platelets Low, Grade 1-2 | 1 | 2 |
| Platelets Low, Grade 3 | 0 | 0 |
| Platelets Low, Grade 4 | 0 | 0 |
| Alanine Aminotransferase High, Grade 1-2 | 1 | 0 |
| Alanine Aminotransferase High, Grade 3 | 0 | 0 |
| Alanine Aminotransferase High, Grade 4 | 0 | 0 |
| Albumin Low, Grade 1-2 | 0 | 3 |
| Albumin Low, Grade 3 | 0 | 0 |
| Albumin Low, Grade 4 | 0 | 0 |
| Alkaline Phosphatase High, Grade 1-2 | 1 | 3 |
| Alkaline Phosphatase High, Grade 3 | 0 | 0 |
| Alkaline Phosphatase High, Grade 4 | 0 | 0 |
| Aspartate Aminotransferase High, Grade 1-2 | 3 | 2 |
| Aspartate Aminotransferase High, Grade 3 | 0 | 0 |
| Aspartate Aminotransferase High, Grade 4 | 0 | 0 |
| Bilirubin High, Grade 1-2 | 0 | 1 |
| Bilirubin High, Grade 3 | 0 | 0 |
| Bilirubin High, Grade 4 | 0 | 0 |
| Calcium Corrected for Albumin Low, Grade 1-2 | 0 | 1 |
| Calcium Corrected for Albumin Low, Grade 3 | 0 | 0 |
| Calcium Corrected for Albumin Low, Grade 4 | 0 | 0 |
| Creatinine High, Grade 1-2 | 1 | 1 |
| Creatinine High, Grade 3 | 0 | 1 |
| Creatinine High, Grade 4 | 0 | 0 |
| Lactate Dehydrogenase High, Grade 1-2 | 3 | 4 |
| Lactate Dehydrogenase High, Grade 3 | 0 | 0 |
| Lactate Dehydrogenase High, Grade 4 | 0 | 0 |
| Potassium Low, Grade 1-2 | 1 | 2 |
| Potassium Low, Grade 3 | 0 | 1 |
| Potassium Low, Grade 4 | 0 | 0 |
| Sodium High, Grade 1-2 | 0 | 1 |
| Sodium High, Grade 3 | 0 | 0 |
| Sodium High, Grade 4 | 0 | 0 |
| Sodium Low, Grade 1-2 | 3 | 1 |
| Sodium Low, Grade 3 | 0 | 0 |
| Sodium Low, Grade 4 | 0 | 0 |
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.
| Months | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria | NA (1.3 to NA) | NA (1.1 to NA) |
OS is defined as the time from date of enrollment to date of death due to any cause.
| Months | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (1.1 to NA) |
CR rate is defined as the percentage of participants with CR according to the modified Lugano Criteria for Response Assessment (Cheson 2014)
| Percentage of Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Rate of Complete Response (CR) Per BICR According to Modified Lugano Response Criteria | 20.0 (0.5 to 71.6) | 66.7 (22.3 to 95.7) |
Objective Response Rate (ORR) is defined as the percentage of participants with CR or PR according to the modified Lugano Criteria for Response Assessment (Cheson 2014) based on investigator assessment
| Percentage of Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| ORR Per Investigator Assessment According to Modified Lugano Response Criteria | 60.0 (14.7 to 94.7) | 83.3 (35.9 to 99.6) |
Duration of response is defined as the time from start of the first documentation of objective tumor response (CR or PR), according to the Modified Lugano Criteria for Response Assessment (Cheson 2007), to the first documentation of objective tumor progression or to death due to any cause, whichever comes first.
| Months | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| DOR Per Investigator Assessment According to Modified Lugano Response Criteria | NA (5.1 to NA) | NA (7.2 to NA) |
PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.
| Months | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Progression-free Survival Per Investigator Assessment According to Modified Lugano Response Criteria | 6.5 (3.2 to NA) | NA (1.1 to NA) |
CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014).
| Percentage of Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria | 40.0 (5.3 to 85.3) | 66.7 (22.3 to 95.7) |
ORR is defined as the percentage of participants with CR or PR, assessed according to Lugano Criteria for Response Assessment (Cheson 2014)
| Percentage of Participants | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| ORR Per BICR According to Lugano Response Criteria | 60.0 (14.7 to 94.7) | 83.3 (35.9 to 99.6) |
Collected over Non-serious Adverse Events, Serious Adverse Events, and All-Cause Mortality were followed for up to 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Classic Hodgkin Lymphoma | 0/6 (0%) | 0/5 (0%) | 5/5 (100%) |
| PTCL | 2/6 (33.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Event | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Gastroenteritis norovirusInfections and infestations | 0/5 | 1/6 |
| Ankle fractureInjury, poisoning and procedural complications | 0/5 | 1/6 |
| Event | Classic Hodgkin Lymphoma | PTCL |
|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 1/5 | 4/6 |
| NauseaGastrointestinal disorders | 2/5 | 1/6 |
| NeutropeniaBlood and lymphatic system disorders | 0/5 | 2/6 |
| FatigueGeneral disorders | 1/5 | 2/6 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/5 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 1/5 | 0/6 |
| Neuropathy peripheralNervous system disorders | 1/5 | 0/6 |
| ParaesthesiaNervous system disorders | 1/5 | 0/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/5 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/5 | 1/6 |
The full analysis set includes participants who received at least one dose of study treatment.
| Age, Categorical(Participants) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 3 | 8 |
| >=65 years | 0 | 3 | 3 |
| Age, Continuous(Years) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| Median | 31 (28 to 55) | 63 (35 to 77) | 50 (28 to 77) |
| Sex: Female, Male(Participants) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 2 | 4 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 4 | 6 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 2 | 3 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Classic Hodgkin Lymphoma | PTCL | Total |
|---|---|---|---|
| Grade 0 | 3 | 2 | 5 |
| Grade 1 | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2019 to primary completion in Nov 2022, 36 months.
Results were first posted in Oct 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin